drugset / Trial / NCT04097002
First in Man Clinical Study to Evaluate Safety and Tolerability of an Oncolytic Adenovirus in Prostate Cancer Patients.
Non-randomizedSequentialOpen-labelTreatment
Summary
This open label, dose escalating study is a phase I/IIa first in man study designed to evaluate the safety and tolerability of intratumoral administration of a novel oncolytic adenovirus (ORCA-010) in treating diagnosed treatment naïve Patients with localized prostate cancer.
Timeline
- Start
- 2019-11-12
- Primary completion
- 2024-10
- Completion
- 2024-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ORCA-010 | Unknown | 1e+11 vg | Other |
| Subject | ORCA-010 | Unknown | 5e+11 vg | Other |
| Subject | ORCA-010 | Unknown | 1.5e+12 vg | Other |